SEC Form 4Coverage since May 22, 2026
$GLUE insider trading
Over the last 12 months, Monte Rosa Therapeutics insiders reported no purchases and 16 sales totaling $2.4M across SEC Form 4 filings. 88% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.4M 16 events
- Events · 12m
- 16 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 88% pre-arranged plans
Side
Price · $GLUE · 12Mvia TradingView
Top insiders · 12m
Champoux JenniferChief Operating Officer5× · $271K
Townson SharonChief Scientific Officer4× · $376K
Warmuth MarkusPresident & CEO3× · $326K
Janku FilipChief Medical Officer3× · $1.2M
Manning Anthony M.—1× · $231K
All insider trades
16 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 9,500 | $23.18 | $220K | -1.6% | — |
| Jul 15, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 4,351 | $23.38 | $102K | -6.5% | plan |
| Jul 6, 2026 | Townson SharonChief Scientific Officer · O | ▼ Sale | 6,000 | $23.31 | $140K | -8.1% | plan · 2 tranches |
| Jun 30, 2026 | Janku FilipChief Medical Officer · O | ▼ Sale | 5,407 | $24.5 | $132K | -8.2% | plan |
| Jun 29, 2026 | Janku FilipChief Medical Officer · O | ▼ Sale | 6,000 | $22.95 | $138K | -9.1% | plan |
| Jun 29, 2026 | Manning Anthony M.D | ▼ Sale | 10,000 | $23.11 | $231K | -100% | — |
| Jun 24, 2026 | Janku FilipChief Medical Officer · O | ▼ Sale | 41,845 | $21.08 | $882K | -41.1% | plan · 2 tranches |
| Jun 23, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 2,175 | $20 | $44K | -3.4% | plan |
| Jun 23, 2026 | Townson SharonChief Scientific Officer · O | ▼ Sale | 3,000 | $20 | $60K | -4.2% | plan |
| Jun 17, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 2,176 | $19 | $41K | -3.4% | plan |
| Jun 17, 2026 | Townson SharonChief Scientific Officer · O | ▼ Sale | 3,000 | $19 | $57K | -4.2% | plan |
| Jun 1, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 468 | $19.73 | $9K | -0.1% | plan |
| Jun 1, 2026 | Warmuth MarkusPresident & CEO · O·D | ▼ Sale | 4,998 | $19.41 | $97K | -0.8% | plan |
| May 29, 2026 | Townson SharonChief Scientific Officer · O | ▼ Sale | 6,000 | $19.87 | $119K | -8.1% | plan |
| May 27, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 2,175 | $20 | $44K | -3.4% | plan |
| May 22, 2026 | Champoux JenniferChief Operating Officer · O | ▼ Sale | 2,176 | $19 | $41K | -3.4% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $GLUE feed.